Correlation between HER2 Overexpression and Clinicopathological Characteristics in Gastric Cancer Patients Who Have Undergone Curative Resection |
Son, Ho Sung
(Department of Surgery, Kosin University College of Medicine)
Shin, Yeon Myung (Department of Surgery, Kosin University College of Medicine) Park, Kwang Kuk (Department of Surgery, Kosin University College of Medicine) Seo, Kyung Won (Department of Surgery, Kosin University College of Medicine) Yoon, Ki Young (Department of Surgery, Kosin University College of Medicine) Jang, Hee Kyung (Department of Pathology, Kosin University College of Medicine) Lee, Sang-Ho (Department of Surgery, Kosin University College of Medicine) Yang, Song I (Department of Surgery, Kosin University College of Medicine) Kim, Jeong Hoon (Department of Surgery, Kosin University College of Medicine) |
1 | National Cancer Institute. SEER Cancer Statistics Review, 1975-2006 [Internet]. Bethesda (MD): National Cancer Institute; 2009 [cited 2010 Mar 5]. Available from: http://www. joplink.net/prev/201003/ref/16-001.html. |
2 | Jørgensen JT, Hersom M. HER2 as a Prognostic marker in gastric cancer: a systematic analysis of data from the literature. J Cancer 2012;3:137-144. DOI ScienceOn |
3 | Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010;17:1471-1474. DOI ScienceOn |
4 | Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI, et al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 1984;312:513-516. DOI ScienceOn |
5 | Sakai K, Mori S, Kawamoto T, Taniguchi S, Kobori O, Morioka Y, et al. Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas. J Natl Cancer Inst 1986;77:1047-1052. |
6 | Sheng WQ, Huang D, Ying JM, Lu N, Wu HM, Liu YH, et al. HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance. Ann Oncol 2013;24:2360-2364. DOI ScienceOn |
7 | Moelans CB, Milne AN, Morsink FH, Offerhaus GJ, van Diest PJ. Low frequency of HER2 amplification and overexpression in early onset gastric cancer. Cell Oncol (Dordr) 2011;34:89-95. |
8 | Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-331. DOI ScienceOn |
9 | Oren M. Lonely no more: p53 finds its kin in a tumor suppressor haven. Cell 1997;90:829-832. DOI ScienceOn |
10 | Kim MA, Jung EJ, Lee HS, Lee HE, Jeon YK, Yang HK, et al. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. Hum Pathol 2007;38:1386-1393. DOI ScienceOn |
11 | Marx AH, Tharun L, Muth J, Dancau AM, Simon R, Yekebas E, et al. HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol 2009;40:769-777. DOI ScienceOn |
12 | Toikkanen S, Helin H, Isola J, Joensuu H. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30- year follow-up. J Clin Oncol 1992;10:1044-1048. DOI |
13 | Kunz PL, Mojtahed A, Fisher GA, Ford JM, Chang DT, Balise RR, et al. HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. Appl Immunohistochem Mol Morphol 2012;20:13-24. DOI |
14 | Im SA, Kim JW, Kim JS, Kim MA, Jordan B, Pickl M, et al. Clinicopathologic characteristics of patients with stage III/IV (M(0)) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization. Diagn Mol Pathol 2011;20:94-100. DOI ScienceOn |
15 | Boers JE, Meeuwissen H, Methorst N. HER2 status in gastrooesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH). Histopathology 2011;58:383-394. DOI |
16 | Seshadri R, Horsfall DJ, Firgaira F, McCaul K, Setlur V, Chalmers AH, et al. The relative prognostic significance of total cathepsin D and HER-2/neu oncogene amplification in breast cancer. The South Australian Breast Cancer Study Group. Int J Cancer 1994;56:61-65. |
17 | Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, Mc-Guire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182. DOI ScienceOn |
18 | Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, Yamashita J, et al. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999;85:1894-1902. DOI |
19 | Tanner M, Hollmen M, Junttila TT, Kapanen AI, Tommola S, Soini Y, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005;16:273-278. DOI ScienceOn |
20 | Latif Z, Watters AD, Bartlett JM, Underwood MA, Aitchison M. Gene amplification and overexpression of HER2 in renal cell carcinoma. BJU Int 2002;89:5-9. DOI |
21 | Hede K. Gastric cancer: trastuzumab trial results spur search for other targets. J Natl Cancer Inst 2009;101:1306-1307. DOI |
22 | Ross JS, McKenna BJ. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 2001;19:554-568. DOI ScienceOn |
23 | Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastrooesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-697. DOI ScienceOn |
24 | Yan B, Yau EX, Bte Omar SS, Ong CW, Pang B, Yeoh KG, et al. A study of HER2 gene amplification and protein expression in gastric cancer. J Clin Pathol 2010;63:839-842. DOI ScienceOn |